Products Categories
| CAS No.: | 58-74-2 |
|---|---|
| Name: | PAPAVERINE HYDROCHLORIDE |
| Article Data: | 73 |
| Molecular Structure: | |
|
|
|
| Formula: | C20H21 N O4 |
| Molecular Weight: | 339.391 |
| Synonyms: | Isoquinoline,6,7-dimethoxy-1-veratryl- (8CI);6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)isoquinoline; 6,7-Dimethoxy-1-veratrylisoquinoline;NSC 136630; Papaverin; Papaverine |
| EINECS: | 200-397-2 |
| Density: | 1.161g/cm3 |
| Melting Point: | 226 °C |
| Boiling Point: | 483.2°Cat760mmHg |
| Flash Point: | 172.2°C |
| Solubility: | 37.33mg/L(37.5 oC) |
| Hazard Symbols: | Toxic narcotic. |
| Risk Codes: | 22 |
| Safety: | Poison by ingestion, intramuscular, subcutaneous, intradermal, intraperitoneal, and intravenous routes. Human systemic effects: coma, somnolence. Its central nervous system action is about midway between those of morphine and codeine, and large doses do not produce the amount of excitement caused by codeine or the soporific action of morphine. Mutation data reported. A cerebral vasodilator and smooth muscle relaxant. Combustible when exposed to heat or flame. When heated to decomposition it emits toxic fumes of NOx. See also (−)-MORPHINE. |
| PSA: | 49.81000 |
| LogP: | 3.86000 |
- 81281-59-67-Benzylideneaminotheophylline
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 68439-39-4Poly(oxy-1,2-ethanediyl), alpha-(2-ethylhexyl)-omega-hydroxy-,
- 852475-26-4MC1568
- 958254-66-51H-Imidazo[4,5-b]pyridine-2-carboxaldehyde, 1-methyl-, hydrochloride
- 99170-93-1N-Methyl-2-oxazolamine
- 717878-06-31-(4-fluorophenyl)-4-nitro-1H-imidazole
- 914458-26-7[5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-Methanone
- 894852-01-87-BROMO-2,2-DIMETHYL-2H-PYRIDO[3,2-B][1,4]OXAZIN-3(4H)-ONE
This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.
Chemistry
IUPAC Name: 1-[(3,4-Dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline
Synonyms of Papaverine (CAS NO.58-74-2) : 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline ; 1-{[3,4-bis(Methyloxy)phenyl]methyl}-6,7-bis(methyloxy)isoquinoline ; 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)isoquinoline ; Isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-
CAS NO: 58-74-2
Molecular Formula:C20H21NO4
Molecular Weight :339.385
Molecular Structure :.png)
EINECS: 200-502-1
Index of Refraction:1.587
Surface Tension: 41.8 dyne/cm
Density: 1.161 g/cm3
Flash Point: 172.2 °C
Enthalpy of Vaporization: 71.98 kJ/mol
Boiling Point: 483.2 °C at 760 mmHg
Vapour Pressure: 5.01E-09 mmHg at 25°C
Melting Point: 226 °C
Solubility : H2O: 25 mg/mL
Appearance: white powder
Uses
Papaverine (CAS NO.58-74-2) is approved to treat spasms of the gastrointestinal tract, bile ducts and ureter and for use as a cerebral and coronary vasodilator in subarachnoid hemorrhage (combined with balloon angioplasty) and coronary artery bypass surgery.Papaverine may also be used as a smooth muscle relaxant in microsurgery where it is applied directly to blood vessels.
It is also commonly used in cryopreservation of blood vessels along with the other glycosaminoglycans and protein suspensions. Functions as a vasodilator during cryopreservation when used in conjunction with verapamil, phentolamine, nifedipine, tolazoline or nitroprusside.
Papaverine is also being investigated as a topical growth factor in tissue expansion with some success.
Papaverine is also present in combinations of opium alkaloid salts such as Omnopon, Pantopon, Papaveretum, and others along with morphine, codeine, and in some cases noscapine and others in a percentage similar to that in opium or modified for a given application.
Toxicity Data With Reference
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| cat | LDLo | subcutaneous | 120mg/kg (120mg/kg) | "Ueber die Wirkung Verschiedener Gifte Auf Vogel, Dissertation," Forchheimer, L., Pharmakologischen Institut der Universitat Wurzburg, Fed. Rep. Ger., 1931Vol. -, Pg. -, 1931. | |
| dog | LDLo | subcutaneous | 120mg/kg (120mg/kg) | "Ueber die Wirkung Verschiedener Gifte Auf Vogel, Dissertation," Forchheimer, L., Pharmakologischen Institut der Universitat Wurzburg, Fed. Rep. Ger., 1931Vol. -, Pg. -, 1931. | |
| frog | LDLo | parenteral | 225mg/kg (225mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) CARDIAC: PULSE RATE GASTROINTESTINAL: NAUSEA OR VOMITING | Journal of Pharmacology and Experimental Therapeutics. Vol. 25, Pg. 35, 1925. |
| frog | LDLo | subcutaneous | 140mg/kg (140mg/kg) | "Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1289, 1935. | |
| man | TDLo | intramuscular | 1143ug/kg (1.143mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: COMA | European Journal of Clinical Pharmacology. Vol. 33, Pg. 651, 1988. |
| mouse | LD50 | intradermal | 150mg/kg (150mg/kg) | BEHAVIORAL: EXCITEMENT BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 59, Pg. 149, 1938. |
| mouse | LD50 | intramuscular | 175mg/kg (175mg/kg) | Archivum Immunologiae et Therapiae Experimentalis. Vol. 15, Pg. 415, 1967. | |
| mouse | LD50 | intraperitoneal | 91mg/kg (91mg/kg) | United States Patent Document. Vol. #4738965, | |
| mouse | LD50 | intravenous | 25mg/kg (25mg/kg) | BEHAVIORAL: EXCITEMENT BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 59, Pg. 149, 1938. |
| mouse | LD50 | oral | 162mg/kg (162mg/kg) | Therapie. Vol. 14, Pg. 731, 1959. | |
| mouse | LD50 | subcutaneous | 170mg/kg (170mg/kg) | Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 227, Pg. 129, 1955. | |
| pigeon | LDLo | subcutaneous | 150mg/kg (150mg/kg) | "Ueber die Wirkung Verschiedener Gifte Auf Vogel, Dissertation," Forchheimer, L., Pharmakologischen Institut der Universitat Wurzburg, Fed. Rep. Ger., 1931Vol. -, Pg. -, 1931. | |
| rabbit | LD50 | intravenous | 25mg/kg (25mg/kg) | BEHAVIORAL: EXCITEMENT BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 59, Pg. 149, 1938. |
| rabbit | LDLo | oral | 190mg/kg (190mg/kg) | "Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1289, 1935. | |
| rabbit | LDLo | subcutaneous | 250mg/kg (250mg/kg) | "Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1289, 1935. | |
| rat | LD50 | intraperitoneal | 59600ug/kg (59.6mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 20, Pg. 1338, 1970. | |
| rat | LD50 | intravenous | 13300ug/kg (13.3mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 26, Pg. 2172, 1976. | |
| rat | LD50 | oral | 325mg/kg (325mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 20, Pg. 1338, 1970. | |
| rat | LD50 | subcutaneous | 151mg/kg (151mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 20, Pg. 1338, 1970. |
Safety Profile
Poison by ingestion, intramuscular, subcutaneous, intradermal, intraperitoneal, and intravenous routes. Human systemic effects: coma, somnolence. Its central nervous system action is about midway between those of morphine and codeine, and large doses do not produce the amount of excitement caused by codeine or the soporific action of morphine. Mutation data reported. A cerebral vasodilator and smooth muscle relaxant. Combustible when exposed to heat or flame. When heated to decomposition it emits toxic fumes of NOx. See also (−)-MORPHINE.
Hazard Codes 
Xn
Risk Statements :22
R22:Harmful if swallowed.
Safety Statements 22
S22:Do not breathe dust.
RIDADR: UN 1544 6.1/PG 3
WGK: Germany 1
RTECS: NW8575000
F :8
HazardClass: 6.1(a)
PackingGroup: II
Specification
Side effects: Frequent side effects of Papaverine (CAS NO.58-74-2) treatment include polymorphic ventricular tachycardia, constipation, interference with sulphobromophthalein retention test (used to determine hepatic function), increased transaminase levels, increased alkaline phosphatase levels, somnolence, and vertigo.
Rare side effects include flushing of the face, hyperhidrosis (excessive sweating), cutaneous eruption, arterial hypotension, tachycardia, loss of appetite, jaundice, eosinophilia, thrombopenia, mixed hepatitis, headache, allergic reaction, chronic active hepatitis, and paradoxical aggravation of cerebral vasospasm.